JP7826294B2 - Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法 - Google Patents

Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法

Info

Publication number
JP7826294B2
JP7826294B2 JP2023515808A JP2023515808A JP7826294B2 JP 7826294 B2 JP7826294 B2 JP 7826294B2 JP 2023515808 A JP2023515808 A JP 2023515808A JP 2023515808 A JP2023515808 A JP 2023515808A JP 7826294 B2 JP7826294 B2 JP 7826294B2
Authority
JP
Japan
Prior art keywords
pdeiv
condition
disease
compound
mediated disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023515808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541261A (ja
JP2023541261A5 (enExample
Inventor
コプリヴィツァ，ヴーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of JP2023541261A publication Critical patent/JP2023541261A/ja
Publication of JP2023541261A5 publication Critical patent/JP2023541261A5/ja
Priority to JP2026028686A priority Critical patent/JP2026102632A/ja
Application granted granted Critical
Publication of JP7826294B2 publication Critical patent/JP7826294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023515808A 2020-09-10 2021-09-10 Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法 Active JP7826294B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026028686A JP2026102632A (ja) 2020-09-10 2026-02-25 Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076774P 2020-09-10 2020-09-10
US63/076,774 2020-09-10
PCT/US2021/049870 WO2022056265A1 (en) 2020-09-10 2021-09-10 Methods of treating pde iv-mediated diseases or conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026028686A Division JP2026102632A (ja) 2020-09-10 2026-02-25 Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法

Publications (3)

Publication Number Publication Date
JP2023541261A JP2023541261A (ja) 2023-09-29
JP2023541261A5 JP2023541261A5 (enExample) 2024-06-13
JP7826294B2 true JP7826294B2 (ja) 2026-03-09

Family

ID=78080507

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023515808A Active JP7826294B2 (ja) 2020-09-10 2021-09-10 Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法
JP2026028686A Pending JP2026102632A (ja) 2020-09-10 2026-02-25 Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026028686A Pending JP2026102632A (ja) 2020-09-10 2026-02-25 Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法

Country Status (12)

Country Link
US (1) US12622915B2 (enExample)
EP (1) EP4210674A1 (enExample)
JP (2) JP7826294B2 (enExample)
KR (1) KR20230066350A (enExample)
CN (1) CN116507336B (enExample)
AU (1) AU2021338837A1 (enExample)
BR (1) BR112023004214A2 (enExample)
CA (1) CA3191177A1 (enExample)
CL (1) CL2023000648A1 (enExample)
IL (1) IL300628A (enExample)
MX (1) MX2023002539A (enExample)
WO (1) WO2022056265A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025224045A1 (en) * 2024-02-22 2026-08-06 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505502A (ja) 2015-12-24 2019-02-28 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｃｆｔｒ制御因子及びこの使用方法
JP2020531511A (ja) 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
PL378245A1 (pl) 2003-01-09 2006-03-20 Astellas Pharma Inc. Pochodne pirolopirydazyny
WO2007142929A2 (en) 2006-05-31 2007-12-13 The University Of North Carolina At Chapel Hill Novel pde4 inhibitors
US8080563B2 (en) * 2006-07-07 2011-12-20 Kalypsys Bicyclic heteroaryl inhibitors of PDE4
TWI845795B (zh) * 2019-12-05 2024-06-21 美商汎達製藥公司 眼用醫藥組合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505502A (ja) 2015-12-24 2019-02-28 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｃｆｔｒ制御因子及びこの使用方法
JP2020531511A (ja) 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medical Chemistry，2017年，Vol.60，pp.1210-1218

Also Published As

Publication number Publication date
AU2021338837A1 (en) 2023-04-06
WO2022056265A1 (en) 2022-03-17
JP2023541261A (ja) 2023-09-29
BR112023004214A2 (pt) 2023-04-11
CA3191177A1 (en) 2022-03-17
IL300628A (en) 2023-04-01
US20230364100A1 (en) 2023-11-16
KR20230066350A (ko) 2023-05-15
CN116507336A (zh) 2023-07-28
EP4210674A1 (en) 2023-07-19
CL2023000648A1 (es) 2023-10-13
JP2026102632A (ja) 2026-06-23
MX2023002539A (es) 2023-03-14
US12622915B2 (en) 2026-05-12
CN116507336B (zh) 2026-01-02

Similar Documents

Publication Publication Date Title
JP7368419B2 (ja) アルドース還元酵素阻害剤およびその使用方法
KR101217303B1 (ko) 9-치환-8-옥소아데닌 화합물
JP6430670B2 (ja) アルドース還元酵素阻害剤および同使用方法
CN103119047B (zh) 三环类蛋白酶体活性增强化合物
EA005824B1 (ru) СОЕДИНЕНИЯ, ЭФФЕКТИВНЫЕ В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ PDE4
JP2016505040A (ja) アルドース還元酵素阻害剤およびその使用
JP7699592B2 (ja) グリシン輸送阻害剤を用いて骨髄性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球生成性ポルフィリン症を処置する方法
CN100349893C (zh) 用作磷酸二酯酶抑制剂的取代2,4－二氢－吡咯并[3,4－b]喹啉－9－酮衍生物
CA2561303A1 (en) Gossypol co-crystals and the use thereof
CN116916929A (zh) 吡咯并吡啶衍生物用于预防或治疗发炎疾病的新颖用途
JP2025185105A (ja) タンパク質キナーゼ阻害剤としてのヘテロ環化合物の新規塩およびこれらの用途
US20130035321A1 (en) Compounds for the treatment of ocular cancer
JP2023541261A (ja) Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法
JP2024509267A (ja) リボソーム障害に関連する貧血を処置するための組成物および方法
JP2024170448A (ja) メイソインジゴの多形体およびメイソインジゴの改変された製剤
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
JP4235000B2 (ja) 糸球体疾患治療剤
WO2024193509A1 (zh) 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
US20250353808A1 (en) 5-methoxymethyl and 5-hydroxymethyl phenethylamines
CN109280028B (zh) 喹啉类化合物及其在dpp-4酶抑制剂的应用
JP5561648B2 (ja) ロダシアニン誘導体及びリーシュマニア感染症治療用医薬組成物
JP4638736B2 (ja) 新規のベンゾナフチリジン
HK40108829A (en) Shp2 inhibitor monotherapy and uses thereof
WO2025217471A1 (en) 2-hemifly phenethylamines
EP4422747A1 (en) Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260225

R150 Certificate of patent or registration of utility model

Ref document number: 7826294

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150